A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), or Post–Essential Thrombocythemia MF (Post–ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
- Shortt, Jake (Primary Chief Investigator (PCI))
Project: Research